Postexposure prophylaxis for HIV following sexual exposure
- PMID: 20543608
- DOI: 10.1097/COH.0b013e32833a5e6c
Postexposure prophylaxis for HIV following sexual exposure
Abstract
Purpose of review: Postexposure prophylaxis (PEP) has become an important part of combined approaches to the prevention of onward HIV transmission. As PEP becomes more widely available after sexual as well as occupational exposure, there are ongoing debates about cost-effectiveness and utility. Different regions have adopted different PEP strategies and the availability of new antiretroviral drugs and classes means that options for PEP regimens are increasing. This review is timely and of importance as it summarizes the evidence supporting current PEP usage and discusses potential future strategies for PEP prescribing.
Recent findings: This review covers the biology and risk of HIV transmission and evidence supporting the use of PEP. It gives a summary of current guidelines including which agents to use, the potential for drug-drug interactions, possible alternative and potential novel PEP regimens, cost-effectiveness and research on effects of PEP on sexual behaviour.
Summary: While reinforcing current practice around PEP prescribing, this review discusses possible future developments including the use of new antiretroviral drugs, new classes of antiretroviral drugs or novel strategies for PEP which are likely to be areas of research in the near future.
Similar articles
-
Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.Arch Intern Med. 1997 Sep 22;157(17):1972-80. Arch Intern Med. 1997. PMID: 9308509
-
[Post-exposure HIV prevention within and outside the hospital].Ther Umsch. 1998 May;55(5):289-94. Ther Umsch. 1998. PMID: 9643126 Review. German.
-
Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004.Sex Transm Dis. 2007 May;34(5):288-93. doi: 10.1097/01.olq.0000237838.43716.ee. Sex Transm Dis. 2007. PMID: 16980918
-
Postexposure prophylaxis after sexual exposure to HIV.Curr Opin Infect Dis. 2007 Feb;20(1):39-46. doi: 10.1097/QCO.0b013e328012c5e0. Curr Opin Infect Dis. 2007. PMID: 17197880 Review.
-
Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.Arch Intern Med. 2004 Jan 12;164(1):46-54. doi: 10.1001/archinte.164.1.46. Arch Intern Med. 2004. PMID: 14718321
Cited by
-
Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination.Viruses. 2025 May 26;17(6):756. doi: 10.3390/v17060756. Viruses. 2025. PMID: 40573348 Free PMC article. Review.
-
Clinical use of CCR5 inhibitors in HIV and beyond.J Transl Med. 2011 Jan 27;9 Suppl 1(Suppl 1):S9. doi: 10.1186/1479-5876-9-S1-S9. J Transl Med. 2011. PMID: 21284908 Free PMC article. Review.
-
HIV awareness and prevention strategies among transgender women in the Eastern and Southern United States: findings from the LITE Study.J Int AIDS Soc. 2022 Oct;25 Suppl 5(Suppl 5):e25999. doi: 10.1002/jia2.25999. J Int AIDS Soc. 2022. PMID: 36225140 Free PMC article.
-
Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Combine! Study): protocol for a pragmatic clinical trial at public healthcare clinics in Brazil.BMJ Open. 2015 Aug 25;5(8):e009021. doi: 10.1136/bmjopen-2015-009021. BMJ Open. 2015. PMID: 26307622 Free PMC article. Clinical Trial.
-
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.PLoS One. 2015 Nov 11;10(11):e0142534. doi: 10.1371/journal.pone.0142534. eCollection 2015. PLoS One. 2015. PMID: 26559816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous